RT Journal Article
T1 The Neuropeptide VIP Limits Human Osteoclastogenesis: Clinical Associations with Bone Metabolism Markers in Patients with Early Arthritis
A1 Castro Vázquez, David
A1 Lamana Rodríguez, Amalia
A1 Arribas Castaño, Paula
A1 Gutiérrez Cañas, Irene
A1 Villanueva Romero, Raúl
A1 Pérez García, Selene
A1 Martínez Mora, María Del Carmen
A1 Juarranz Moratilla, Yasmina
A1 Fernández de Córdoba, Sara
A1 González Álvaro, Isidoro
A1 Gomáriz, Rosa P.
A1 Carrión Caballo, Mar
AB We aimed to evaluate the direct action of VIP on crucial molecules involved in human osteoclast differentiation and function. We also investigated the relationship between VIP serum levels and bone remodeling mediators in early arthritis patients. The expression of VIP receptors and osteoclast gene markers in monocytes and in vitro differentiated osteoclasts was studied by real-time PCR. NFATc1 activity was measured using a TransAM® kit. Osteoclastogenesis was confirmed by quantification of tartrate-resistant acid phosphatase positive multinucleated cells. OsteoAssay® Surface Multiple Well Plate was used to evaluate bone-resorbing activity. The ring-shaped actin cytoskeleton and the VPAC1 and VPAC2 expression were analyzed by immunofluorescence. We described the presence of VIP receptors in monocytes and mature osteoclasts. Osteoclasts that formed in the presence of VIP showed a decreased expression of osteoclast differentiation gene markers and proteolytic enzymes involved in bone resorption. VIP reduced the resorption activity and decreased both β3 integrin expression and actin ring formation. Elevated serum VIP levels in early arthritis patients were associated with lower BMD loss and higher serum OPG concentration. These results demonstrate that VIP exerts an anti-osteoclastogenic action impairing both differentiation and resorption activity mainly through the negative regulation of NFATc1, evidencing its bone-protective effects in humans.
PB MDPI
YR 2021
FD 2021-12-10
LK https://hdl.handle.net/20.500.14352/4899
UL https://hdl.handle.net/20.500.14352/4899
LA eng
NO Castro Vázquez, D., Lamana Rodríguez, A., Arribas Castaño, P. et al. «The Neuropeptide VIP Limits Human Osteoclastogenesis: Clinical Associations with Bone Metabolism Markers in Patients with Early Arthritis». Biomedicines, vol. 9, n.o 12, diciembre de 2021, p. 1880. Crossref, https://doi.org/10.3390/biomedicines9121880.
NO Instituto de Salud Carlos III/Fondo Europeo de Desarrollo Regional
DS Docta Complutense
RD 11 abr 2025